CLOSE

Now Commenting On:

Independent program administrator issues annual report

Major League Baseball and the Major League Baseball Players Association today released the annual public report from the Joint Drug Prevention and Treatment Program's Independent Program Administrator.  The Joint Drug Prevention and Treatment Program calls for a public report to be issued by December 1st of each year.

The accompanying report from the Independent Program Administrator, Jeffrey M. Anderson, M.D., covers the period from the beginning of the 2011-2012 off-season through the end of Major League Baseball's 2012 Postseason.

2012 Public Report of Major League Baseball’s

More

Joint Drug Prevention and Treatment Program

This report covers the time from the beginning of the 2011-2012 Major League Baseball off-season to the end of the 2012 Major League Baseball post-season. As per agreement between Major League Baseball and the Major League Baseball Players Association, the following report is specific to players who compose forty-man rosters for Major League Baseball clubs.

  1. The total number of drug tests that were collected and analyzed for performance enhancing substances and/or stimulants during the time listed above was 5136 tests. This total includes 3955 urine tests and 1181 blood tests.
  1. Eighteen tests were reported by the testing laboratory for having an adverse analytical finding that resulted in discipline. The substances reported were as follows:

Performance Enhancing Substances (7)

Clenbuterol (1)

Clostebol (1)

Tamoxifen (1)

Testosterone (4)

                Stimulants (11)

Adderall (10)

d-amphetamine (1)

3)   119 Therapeutic Use Exemptions were granted. The diagnoses were as follows:

Attention Deficit Disorder: 116

Hypertension: 2

Hypogonadism: 1

Respectfully submitted,

Jeffrey M. Anderson, MD

Independent Program Administrator

Major League Baseball’s Joint Drug Prevention and Treatment Program

Less
{}
{}